Publications by authors named "J F Pagel"

Objective: We hypothesized that previously healthy infants < 90 days of age with late-onset sepsis (LOS) have disturbances of the gut microbiome with yet undefined specific immunological patterns.

Methods: We performed a prospective single-center convenience sample study between January 2019 and July 2021 in a case-control design. Routine diagnostics included conventional cultures (blood, cerebrospinal fluid, urine), PCRs and inflammatory markers in infants aged < 90 days with clinical LOS.

View Article and Find Full Text PDF

Background: Little is known about specific safety aspects in children with significant comorbidities receiving the mRNA vaccine BNT162b2, as approval studies did not address this population. This study's purpose is to evaluate safety and adverse events in these children compared to healthy children.

Methods: In this prospective, multicentre, industry-independent cohort study, caregivers whose children received BNT162b2 were asked to participate in an online questionnaire.

View Article and Find Full Text PDF

Filamentous fungi cultivated as biopellets are well established in biotechnology industries. A distinctive feature of filamentous fungi is that hyphal growth and fungal morphology affect product titers and require tailored process conditions. Within the pellet, mass transfer, substrate consumption, and biomass formation are intricately linked to the local hyphal fraction and pellet size.

View Article and Find Full Text PDF
Article Synopsis
  • The SIERRA trial aimed to improve outcomes for older patients with relapsed or refractory acute myeloid leukemia (RR AML) by comparing a new treatment, I-apamistamab, against standard care before bone marrow transplant.
  • The study involved 153 patients, with results showing a significantly higher durable complete remission (dCR) rate of 17.1% for the I-apamistamab group compared to 0% for the conventional care group.
  • Although the overall survival rates were similar between the two groups, the I-apamistamab regimen exhibited more promise for achieving long-lasting remission with similar levels of severe side effects.
View Article and Find Full Text PDF